Long-acting parathyroid hormone (1-34) prodrug
Palopegteriparatide
Brand names: Yorvipath
Adult dose
Dose: Initial 18 micrograms SC OD; titrate per BNF/SmPC
Route: SC
Frequency: OD
Clinical pearls
- Chronic hypoparathyroidism in adults; specialist endocrine
Contraindications
- Pregnancy
- Hypersensitivity
Side effects
- Hypercalcaemia
- Hypocalcaemia
- Headache
- Diarrhoea
- Polyuria
- Increased risk of osteosarcoma (theoretical)
Interactions
- Calcium and active vitamin D — frequent dose adjustment as titrating
Monitoring
- Serum calcium
- Phosphate
- 24h urinary calcium
- Renal function
Reference: BNF; SmPC; https://bnf.nice.org.uk/drugs/palopegteriparatide/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Pathways
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Adult Hypoglycaemia (Treated Diabetes) · JBDS-IP (2023): Hospital Management of Hypoglycaemia
- Adrenal Crisis · Society for Endocrinology Emergency Guidance (2024)
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016